# Aetiology of anaemia and public health implications in the Taabo health demographic surveillance system, south-central Côte divoire

Submission date	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li><li>Protocol</li></ul>		
09/11/2012				
Registration date	Overall study status	Statistical analysis plan		
29/11/2012	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
21/10/2016	Infections and Infestations			

## Plain English summary of protocol

Background and study aims

Anaemia is caused when there aren't enough red blood cells or haemoglobin (the part of the red blood cell that carries oxygen) to meet the body's needs. Anaemia affects more than two billion people worldwide and is a huge public health problem in developing countries. For instance, it is currently estimated that in Africa, about half of the children and women of childbearing age are at risk of anaemia. It is commonly thought that lack of iron is the main cause for anaemia. However, anaemia can result from other diet deficiencies, as well as from parasitic diseases such as malaria and helminthiases (worm infection), or from genetic disorders such as haemoglobinopathies. The aim of this study is to find out which factors (e.g., nutrient deficiencies, parasitic infections) are associated with anaemia in different population groups in a typical rural setting of Côte d'Ivoire, West Africa.

# Who can participate?

Infants (aged 6-23 months), young school-aged children (aged 6-8 years) and young women (aged 15-25 years) living in one of the three selected localities

#### What does the study involve?

Participants are assessed to see how haemoglobin concentration changes over time in response to specific health interventions (e.g., treatments and preventive chemotherapy against soil-transmitted helminthiasis and schistosomiasis, and treatments of clinical malaria and severe anaemia cases). Additionally, the prevalence of haemoglobinopathies (genetic defect that affects haemoglobin) is determined in the study area. The participants undergo tests, namely examination of blood, urine and faeces samples for parasites, and haemoglobin measurements. These tests are conducted at the start of the study and at four further follow-up surveys once every 3-4 months. Moreover, a blood sample is collected at the start of the study, after 6 months and at the end-of-study survey.

What are the possible benefits and risks of participating?

Findings from this study will increase knowledge about anaemia in West Africa, which might lead to suggestions on how to locally better prevent and control anaemia. Participants are examined

regularly over a 14-month period by qualified medical staff. Participants are treated if a clinical malaria episode or a helminth infection is diagnosed, according to national guidelines. These treatments might result in some adverse events, which are usually brief. All personnel who perform the medical examinations and treatment are qualified and well experienced (i.e. medical doctors, nurses and technicians who are well acquainted to do this type of work). All methods applied within the study are routinely used in the field, the laboratories and the hospitals and therefore do not place participants under any specific risk. Particular care is taken when sampling blood, as there are small risks such as bruise, infection and/or inflammation of the vein, and discomfort at the time of taking a blood sample. These risks are minimized by doing the blood collection with all the precautions using sterile material and performed only by experienced staff.

Where is the study run from? Taabo HDSS (Côte d'Ivoire)

When is the study starting and how long is it expected to run for? April 2010 to June 2011

Who is funding the study?
Swiss National Science Foundation (Switzerland)

Who is the main contact? Prof. Jürg Utzinger juerg.utzinger@unibas.ch

# Contact information

Type(s)

Scientific

#### Contact name

Prof Jürg Utzinger

#### Contact details

Swiss Tropical and Public Health Institute
Department of Epidemiology and Public Health
Basel
Switzerland
CH-4002
+41 (0)61 284-8129
juerg.utzinger@unibas.ch

# Additional identifiers

**Protocol serial number** N/A

# Study information

Scientific Title

Aetiology of anaemia and public health implications in the Taabo health demographic surveillance system, south-central Côte divoire

## **Study objectives**

Anaemia is associated with sociodemographic variables, micronutrient deficiencies, parasitic infections and inflammatory parameters and these associations depend on the host age and sex.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

- 1. Ethikkommission beider Basel (EKBB), Switzerland, 10/10/2010, ref: 252/09 (Amendment 17/04/2010)
- 2. Comité National dÉthique et de la Recherche, Ministère de la Santé et de lHygiène publique, 23/03/2010, ref: 1086 MSHP/CNER

## Study design

Prospective longitudinal trials

#### Primary study design

Observational

## Study type(s)

Screening

# Health condition(s) or problem(s) studied

Anaemia, malaria, helminth infection

#### **Interventions**

Non-pregnant participants who were diagnosed with soil-transmitted helminths at the baseline or at one of the four further follow-up surveys:

- 1. Single-dose albendazole (400 mg for school-aged children and women and 200 mg for infants) Participants who were diagnosed with Schistosoma mansoni or S. haematobium at the baseline or at one of the four further follow-up surveys:
- 2. Single-dose praziquantel (40 mg/kg for children >2 years old)

Suspected clinical malaria cases (defined by a positive rapid diagnostic test (RDT) and tympanic temperature >38°C):

- 3. artesunate-amodiaquine (infants: 25 mg + 67.5 mg/day for 3 days; children: 100 mg + 270 mg/day for 3 days; women:  $2 \times 100 \text{ mg} + 270 \text{ mg/day}$  for 3 days)
- Severely anaemic participants (i.e., haemaglobin level <8 g/dl, according to national guidelines of Côte dIvoire) with a positive RDT for malaria
- 4. treatment with artesunate-amodiaquine or referral to the nearest health center if their RDT is negative.

# Intervention Type

Other

#### Phase

Not Applicable

# Primary outcome(s)

## Haemoglobin concentration

## Key secondary outcome(s))

- 1. Iron status indicators
- 2. Parasitic infection variables

## Completion date

28/06/2011

# Eligibility

## Key inclusion criteria

- 1. Infants, aged 6-23 months (males and females); children aged 6-8 years (males and females); and women aged 15-25 years at the baseline cross-sectional survey
- 2. Participants will be randomly selected from an existing database kept by the Taabo HDSS
- 3. Written informed consent (or fingerprint for illiterate people) of school-aged children, women and a parent/guardian of infants and school-aged children at baseline or at one of the four further cross-sectional surveys
- 4. Written approval of the study physician

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Mixed

#### Sex

All

## Key exclusion criteria

People who are severely ill, as judged by the study physician.

#### Date of first enrolment

15/04/2010

#### Date of final enrolment

28/06/2011

# Locations

#### Countries of recruitment

Côte d'Ivoire

Switzerland

# Study participating centre Swiss Tropical and Public Health Institute Basel Switzerland CH-4002

# Sponsor information

#### Organisation

Swiss National Science Foundation (SNSF) (Switzerland)

#### **ROR**

https://ror.org/00yjd3n13

# Funder(s)

## Funder type

Government

#### **Funder Name**

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (ref: IZ70Z0\_123900)

## Alternative Name(s)

Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, The Swiss National Science Foundation (SNSF), SNF, SNSF, FNS

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Trusts, charities, foundations (both public and private)

#### Location

**Switzerland** 

#### **Funder Name**

Eremitage Fund of the Rudolf Geigy-Foundation (Switzerland)

# Funder Name

Fairmed (Switzerland)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

# **Study outputs**

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2012	Yes	No
Results article	results	01/11/2012	Yes	No
Results article	results	01/06/2013	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes